Original Source(s)
Related Content
Healthcare utilization and costs in patients with rheumatoid arthritis using biologics or tofacitinib: a nationwide, population-based study
by Yen-Ju Chen, Wei-Li Ho, Hsian-Min Chen, Yi-Ming Chen, Hsin-Hua Chen
June 22, 2026
Does TYK2/JAK1 Show Potential in Inflammatory Diseases?
Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.
July 6, 2026
-
3 min